Glycoprotein / GP (virus)

Glycoprotein / GP (virus) 詳細

英語名Envelope glycoprotein市販薬剤の数2
治験薬の数2ターゲットの別称GP1,2,GP,Envelope glycoprotein
研究&開発段階Approved
英語名Envelope glycoprotein
ターゲットの別称GP1,2,GP,Envelope glycoprotein
市販薬剤の数2
治験薬の数2
研究&開発段階Approved

お問い合わせ

Glycoprotein / GP (virus)バックグランド

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus)分子の別称

GP,Envelope glycoprotein,GP(1,2)

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Porgaviximab/Larcaviximab/Cosfroviximabc2G4-N; c4G7; c13C6Phase 3 ClinicalMapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology LaboratoryHemorrhagic Fever, Ebola
詳細
MIL-77MIL-77Phase 1 ClinicalBeijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical SciencesHemorrhagic Fever, Ebola
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
AnsuvimabVRC-EBOMAB092-00-AB; MAb114; MAb-114ApprovedNational Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, IslamabadEbangaUnited StatesHemorrhagic Fever, EbolaRidgeback Biotherapeutics Lp2020-12-21Hemorrhagic Fever, Ebola
詳細
Atoltivimab/Maftivimab/OdesivimabREGN3470-3471-3479; REGN-EB3ApprovedRegeneron Pharmaceuticals IncInmazebUnited StatesHemorrhagic Fever, EbolaRegeneron Pharmaceuticals Inc2020-10-14Hemorrhagic Fever, Ebola
詳細
  • 詳細
  • お問い合わせ
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8